EU Clinical Trial 2018-000504-42

A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients with Middle and Advanced Phases of MPS IIIA Disease  May 21, 2019

Main objective of the trial: Primary outcomes of safety and efficacy assessed by measuring biochemical and biophysical changes in middle and advanced phases of MPS IIIA evolution Objetivos principales de seguridad y eficacia evaluado a través de los cambios bioquímicos y biofísicos en la fase media y avanzada de la evolución de la enfermedad MPS IIIA

Parties

Sponsors
Countries
AU ES US
Keywords
Mucopolysaccharidosis III scAAV9.U1A.SGSH

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.